BioPharmSignal logoBioPharmSignal

Biotech News

GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients

GoodRx (GDRX)GoodRxCompany update

Eligible self-pay patients can access the oral diabetes treatment for as low as $149 per month Brief Summary: GoodRx expands access to Ozempic® pill (oral semaglutide) for as low as $149 per month Available at GoodRx’s nationwide pharmacy network Adds an oral option to the Ozempic treatment

Related news

GDRXGoodRx2026-04-09 11:30 EST

GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide

GDRXGoodRx2026-04-15 13:00 EST

GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price

View all latest news

GoodRx

Medication-Savings Platform GoodRx is a U.S. digital platform that helps consumers compare prescription prices and access discounts at pharmacies. Consumer and Provider Network The service connects consumers, pharmacies, pharmacy-benefit managers, manufacturers and healthcare professionals. Users access savings through the website,...

Recent company news

GDRXGoodRx2026-08-05 20:05 EST

GoodRx Reports Second Quarter 2026 Results

GDRXGoodRx2026-07-09 20:05 EST

GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call

GDRXGoodRx2026-05-27 13:00 EST

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

GDRXGoodRx2026-05-06 20:05 EST

GoodRx Reports First Quarter 2026 Results

GDRXGoodRx2026-05-01 12:10 EST

GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients

Stock data

Close
3.72 USD
Market cap
999.09M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States